Keywords: delavirdine, filed, usa, nnrti, role, reviewed, pharmacia
Delavirdine Filed In USA; NNRTI Role Reviewed
Article | 29 July 1996
Pharmacia & Upjohn has filed its New Drug Application in the USA for Rescriptor (delavirdine) a non-nucleoside reverse transcriptase inhibitor, for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
